Concurrent Investment Advisors LLC Reduces Position in IQVIA Holdings Inc. (NYSE:IQV)

Concurrent Investment Advisors LLC decreased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,514 shares of the medical research company’s stock after selling 165 shares during the period. Concurrent Investment Advisors LLC’s holdings in IQVIA were worth $1,084,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. Cumberland Partners Ltd grew its position in shares of IQVIA by 6.0% in the fourth quarter. Cumberland Partners Ltd now owns 1,759 shares of the medical research company’s stock valued at $346,000 after purchasing an additional 99 shares during the period. Ieq Capital LLC grew its position in shares of IQVIA by 109.5% in the fourth quarter. Ieq Capital LLC now owns 41,521 shares of the medical research company’s stock valued at $8,159,000 after purchasing an additional 21,706 shares during the period. Global Retirement Partners LLC grew its position in shares of IQVIA by 1.0% in the fourth quarter. Global Retirement Partners LLC now owns 10,798 shares of the medical research company’s stock valued at $2,122,000 after purchasing an additional 112 shares during the period. Callahan Advisors LLC grew its position in shares of IQVIA by 10.9% in the fourth quarter. Callahan Advisors LLC now owns 35,719 shares of the medical research company’s stock valued at $7,019,000 after purchasing an additional 3,506 shares during the period. Finally, Venturi Wealth Management LLC grew its position in shares of IQVIA by 710.1% in the fourth quarter. Venturi Wealth Management LLC now owns 1,361 shares of the medical research company’s stock valued at $267,000 after purchasing an additional 1,193 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 1.6 %

NYSE:IQV opened at $190.94 on Friday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The business’s 50-day simple moving average is $199.57 and its 200 day simple moving average is $216.49. The stock has a market cap of $33.62 billion, a price-to-earnings ratio of 25.46, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Buying and Selling

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were acquired at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the purchase, the director now owns 1,275 shares in the company, valued at $255,739.50. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Stifel Nicolaus lowered their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Robert W. Baird reduced their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. UBS Group reduced their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Morgan Stanley lifted their target price on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Finally, William Blair reiterated an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $251.22.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.